AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36866660 — intervention group
Group type: EXPERIMENTAL
Intervention: High PCAT attenuation group (n=244)
Number of subjects: 474
Study 36866660 — intervention group
Group type: COMPARATOR
Intervention: Low PCAT attenuation group (n=230)
Number of subjects: 474
Study 36866835 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety group (n=25)
Number of subjects: 54
Study 36866835 — intervention group
Group type: COMPARATOR
Intervention: Non-anxiety group (n=29)
Number of subjects: 54
Study 36866835 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 54
Study 36866838 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg once weekly for 4 weeks followed by every 2 weeks
Number of subjects: 106
Study 36866838 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 2 weeks
Number of subjects: 106
Study 36866838 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 4 weeks
Number of subjects: 106
Study 36866838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab-containing arms (Isa + CemiQ2W and Isa + CemiQ4W)
Number of subjects: 106
Study 36866838 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival
Number of subjects: 106
Study 36866852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 58
Study 36866852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from PREVENT trial)
Number of subjects: 58
Study 36866921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 517
Study 36866921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 36867173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 619
Study 36867173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion augmentation
Number of subjects: 619
Study 36867173 — intervention group
Group type: COMPARATOR
Intervention: Switch to bupropion
Number of subjects: 619
Study 36867173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 619
Study 36867173 — intervention group
Group type: COMPARATOR
Intervention: Switch to nortriptyline
Number of subjects: 619
Study 36867455 — intervention group
Group type: EXPERIMENTAL
Intervention: Woebot for Adolescents (W-GenZD)
Number of subjects: 133
Study 36867455 — intervention group
Group type: COMPARATOR
Intervention: telehealth-delivered CBT-based skills group (CBT-group)
Number of subjects: 133
Study 36867504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban
Number of subjects: 181
Study 36867504 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg apixaban
Number of subjects: 181
Study 36867756 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel targets and models with complex multiscale interaction of data from different sources
Number of subjects: 0
Study 36867756 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific conditions and outcomes
Number of subjects: 0
Study 36867758 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 36867758 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon gamma
Number of subjects: 0
Study 36867910 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glutamate diet (LGD)
Number of subjects: 33
Study 36868179 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided pembrolizumab administration
Number of subjects: 33
Study 36868179 — intervention group
Group type: COMPARATOR
Intervention: History-controlled cohort (pembrolizumab 200 mg 3-weekly for more than four cycles)
Number of subjects: 33
Study 36868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab induction treatment (240 mg every 2 weeks for 4 doses)
Number of subjects: 83
Study 36868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab boost (1 mg/kg plus 3 mg/kg every 3 weeks)
Number of subjects: 83
Study 36868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance treatment
Number of subjects: 83
Study 36868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab induction treatment
Number of subjects: 83
Study 36868261 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab (400 mg loading dose followed by 200 mg monthly)
Number of subjects: 65
Study 36868261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (volume-matched)
Number of subjects: 65
Study 36868261 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab
Number of subjects: 65
Study 36868261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 36868377 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 614
Study 36868377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 36868525 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional review of iPET response assessment
Number of subjects: 573
Study 36868525 — intervention group
Group type: COMPARATOR
Intervention: Central review of iPET response assessment
Number of subjects: 573
Study 36868587 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation (NHFOV)
Number of subjects: 340
Study 36868587 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 340
Study 36868591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cancer treatment and follow-up regimens
Number of subjects: 35
Study 36868591 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a caregiver
Number of subjects: 35
Study 36868591 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 35
Study 36868591 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service configuration
Number of subjects: 35
Study 36868591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer diagnosis
Number of subjects: 35
Study 36868591 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment burden
Number of subjects: 35
Study 36868590 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero Suicide-Usual Care plus ASSIP
Number of subjects: 400
Study 36868590 — intervention group
Group type: COMPARATOR
Intervention: Zero Suicide-Usual Care
Number of subjects: 400
Study 36868593 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) administered at different doses and administration intervals during laparoscopic cholecystectomy (LC)
Number of subjects: 0
Study 36868593 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 0
Study 36868594 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support tool
Number of subjects: 18
Study 36868594 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 18
Study 36868599 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory biomarker analysis, longitudinal characterisation of AECOPD (clinical, functional, and microbial), and identification of host-microbiome interactions.
Number of subjects: 150
Study 36868599 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic sequencing to identify mutations associated with increased risk of AECOPD and microbial infections.
Number of subjects: 150
Study 36868599 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of time-to-first AECOPD modelled using Cox proportional hazards' regression.
Number of subjects: 150
Study 36868877 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 (2 doses, administered intramuscularly 21 days apart)
Number of subjects: 30137
Study 36868877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses, administered intramuscularly 21 days apart)
Number of subjects: 30137
Study 36868877 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019
Number of subjects: 30137
Study 36868914 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment with the BTK inhibitor acalabrutinib and the BCL-2 inhibitor venetoclax
Number of subjects: 0
Study 36868990 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB5 treatment (3 intravenous infusions of 2 × 10)
Number of subjects: 16
Study 36868990 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB5 treatment
Number of subjects: 16
Study 36869148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and laser phototherapy
Number of subjects: 76
Study 36869148 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise alone
Number of subjects: 76
Study 36869208 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular veins compression for 60 seconds to elevate intracranial blood volume and ICP
Number of subjects: 98
Study 36869208 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 98
Study 36869208 — intervention group
Group type: EXPERIMENTAL
Intervention: No surgical procedures (Sk1)
Number of subjects: 98
Study 36869251 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 375
Study 36869251 — intervention group
Group type: COMPARATOR
Intervention: Abatacept placebo + Methotrexate
Number of subjects: 375
Study 36869251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued combination therapy (Abatacept + Methotrexate)
Number of subjects: 375
Study 36869251 — intervention group
Group type: COMPARATOR
Intervention: Abatacept monotherapy
Number of subjects: 375
Study 36869258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-present feedback (n=24)
Number of subjects: 49
Study 36869258 — intervention group
Group type: COMPARATOR
Intervention: Gene-absent feedback (n=25)
Number of subjects: 49
Study 36869290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi program for memory (TCM)
Number of subjects: 41
Study 36869328 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood localization
Number of subjects: 220
Study 36869328 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative colonoscopy
Number of subjects: 220
Study 36869356 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib monotherapy
Number of subjects: 400
Study 36869356 — intervention group
Group type: COMPARATOR
Intervention: tocilizumab monotherapy
Number of subjects: 400
Study 36869364 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior component separation (CS) with transversus abdominis muscle release (TAR) reinforced by retro-muscular mesh
Number of subjects: 202
Study 36869371 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance testing with preemptive isolation and contact precautions
Number of subjects: 1314
Study 36869371 — intervention group
Group type: COMPARATOR
Intervention: Standard precautions
Number of subjects: 1314
Study 36869382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobility level 4-7 (at least active standing)
Number of subjects: 1708
Study 36869382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobility level 1-3 (passive transfer from bed to chair or active sitting)
Number of subjects: 1708
Study 36869382 — intervention group
Group type: COMPARATOR
Intervention: Early mobility level 0 (passive range of motion)
Number of subjects: 1708
Study 36869387 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of Voriconazole (4 mg/kg)
Number of subjects: 48
Study 36869387 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of Voriconazole (6 mg/kg)
Number of subjects: 48
Study 36869387 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of Voriconazole (Vfend®) (4 mg/kg)
Number of subjects: 48
Study 36869387 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of Voriconazole (Vfend®) (6 mg/kg)
Number of subjects: 48
Study 36869392 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus music therapy (MT) during hospitalization and/or during a 6-month period post-discharge
Number of subjects: 213
Study 36869392 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 213
Study 36869392 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus music therapy (MT)
Number of subjects: 213
Study 36869680 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-nerve-targeted group (including traditional genicular nerves plus recurrent fibular and infrapatellar branches of the saphenous nerve)
Number of subjects: 80
Study 36869680 — intervention group
Group type: COMPARATOR
Intervention: 3-nerve-targeted group (traditional genicular nerves only)
Number of subjects: 80
Study 36869680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 36869680 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-nerve-targeted group
Number of subjects: 80
Study 36869794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cinacalcet
Number of subjects: 65
Study 36869794 — intervention group
Group type: COMPARATOR
Intervention: Total parathyroidectomy (PTx)
Number of subjects: 65
Study 36869793 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-Treatment
Number of subjects: 176
Study 36869793 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Treatment (systemic treatment)
Number of subjects: 176
Study 36869878 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered plaque
Number of subjects: 150
Study 36869878 — intervention group
Group type: COMPARATOR
Intervention: Non-layered plaque
Number of subjects: 150
Study 36869909 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plant protein intake
Number of subjects: 177
Study 36869909 — intervention group
Group type: COMPARATOR
Intervention: Decreased plant protein intake
Number of subjects: 177
Study 36869921 — intervention group
Group type: EXPERIMENTAL
Intervention: Just4Us intervention
Number of subjects: 83
Study 36869921 — intervention group
Group type: COMPARATOR
Intervention: Information session (Control)
Number of subjects: 83
Study 36869990 — intervention group
Group type: EXPERIMENTAL
Intervention: MiFi MVG group (n = 75)
Number of subjects: 500
Study 36869990 — intervention group
Group type: COMPARATOR
Intervention: MiFi Conv group (n = 254)
Number of subjects: 500
Study 36869990 — intervention group
Group type: COMPARATOR
Intervention: BLZ Conv group (n = 246)
Number of subjects: 500
Study 36869990 — intervention group
Group type: EXPERIMENTAL
Intervention: MiFi MVG group
Number of subjects: 500
Study 36869990 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 500
Study 36870019 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Intelligence Training (SIT) program (8 hours)
Number of subjects: 230
Study 36870019 — intervention group
Group type: COMPARATOR
Intervention: Attentional Control (AC) condition focusing on healthy lifestyle education
Number of subjects: 230
Study 36870065 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site CT-FFR care pathway using machine learning
Number of subjects: 1216
Study 36870065 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1216
Study 36870070 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (hydrocortisone, vitamin C, and thiamine)
Number of subjects: 106
Study 36870070 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 36870093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone (maximum daily dose of 63 mg/kg/day if ≤28 kg or 1800 mg/day if >28 kg)
Number of subjects: 21
Study 36870093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 36870093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 21
Study 36870358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea starting at 20 mg/kg once daily, escalated every 8 weeks by 5 mg/kg per day to maximum tolerated dose.
Number of subjects: 202
Study 36870358 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the sickle cell anaemia clinic for participants with normal Doppler velocities (<170 cm/s).
Number of subjects: 202
Study 36870360 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion every 21 days)
Number of subjects: 17
Study 36870360 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab monotherapy
Number of subjects: 17
Study 36870409 — intervention group
Group type: EXPERIMENTAL
Intervention: ZB-06 vaginal film containing HC4-N, used as a single dose before intercourse
Number of subjects: 20
Study 36870409 — intervention group
Group type: COMPARATOR
Intervention: No product use (baseline)
Number of subjects: 20
Study 36870409 — intervention group
Group type: COMPARATOR
Intervention: No product use (follow-up visit)
Number of subjects: 20
Study 36870436 — intervention group
Group type: EXPERIMENTAL
Intervention: HR HPV self-sampling
Number of subjects: 400
Study 36870478 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's perception of cleansing quality
Number of subjects: 633
Study 36870478 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Bowel Preparation Scale (BBPS)
Number of subjects: 633
Study 36870528 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Teach-to-Goal (V-TTG)
Number of subjects: 70
Study 36870528 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 70
Study 36870528 — intervention group
Group type: EXPERIMENTAL
Intervention: V-TTG
Number of subjects: 70
Study 36870528 — intervention group
Group type: COMPARATOR
Intervention: BI
Number of subjects: 70
Study 36870528 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 70
Study 36870539 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated mixture of crystalline amino acids and fish oil (ISO)
Number of subjects: 10
Study 36870539 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon ingestion (SAL)
Number of subjects: 10
Study 36870551 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 1050
Study 36870551 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 1050
Study 36870551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both gamification and financial incentives
Number of subjects: 1050
Study 36870551 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 1050
Study 36870572 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control (no portal interventions)
Number of subjects: 213773
Study 36870572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-commitment messages
Number of subjects: 213773
Study 36870572 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct appointment scheduling
Number of subjects: 213773
Study 36870572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-appointment reminder messages
Number of subjects: 213773
Study 36870890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mcg/kg intranasal dexmedetomidine
Number of subjects: 55
Study 36870890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mcg/kg intranasal dexmedetomidine
Number of subjects: 55
Study 36870890 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mcg/kg intranasal dexmedetomidine
Number of subjects: 55
Study 36870890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mcg/kg intranasal dexmedetomidine
Number of subjects: 55
Study 36870941 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil, administered on days 1 and 8, repeated every three weeks for 4 cycles.
Number of subjects: 0
Study 36870941 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil
Number of subjects: 0
Study 36870948 — intervention group
Group type: COMPARATOR
Intervention: Visual Evoked Potentials (VEPs) in Rett syndrome (n=43) and CDKL5 deficiency disorder (n=16)
Number of subjects: 80
Study 36870948 — intervention group
Group type: COMPARATOR
Intervention: Visual Evoked Potentials (VEPs) in MECP2 duplication syndrome (n=15)
Number of subjects: 80
Study 36870948 — intervention group
Group type: COMPARATOR
Intervention: Auditory Evoked Potential (AEP) latency in MECP2 duplication syndrome (n=14) and FOXG1 syndrome (n=6)
Number of subjects: 80
Study 36870948 — intervention group
Group type: COMPARATOR
Intervention: Auditory Evoked Potential (AEP) amplitude in Rett syndrome and CDKL5 deficiency disorder
Number of subjects: 80
Study 36870948 — intervention group
Group type: COMPARATOR
Intervention: Auditory Evoked Potential (AEP) latency in CDKL5 deficiency disorder, MECP2 duplication syndrome, and FOXG1 syndrome
Number of subjects: 80
Study 36870948 — intervention group
Group type: COMPARATOR
Intervention: Visual Evoked Potentials (VEPs) in FOXG1 syndrome (n=5)
Number of subjects: 80
Study 36870947 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 26
Study 36870982 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Caries Removal with Papacarie™ and application Bixa orellana extract (20%) with LED (aPDT)
Number of subjects: 160
Study 36870982 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Caries Removal with Papacarie™ and application Bixa orellana extract (20%)
Number of subjects: 160
Study 36870982 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Caries Removal with Papacarie™
Number of subjects: 160
Study 36870982 — intervention group
Group type: COMPARATOR
Intervention: Caries removal with a low-speed drill
Number of subjects: 160
Study 36871000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily
Number of subjects: 152
Study 36871000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 36871042 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2811 (500 mg; Day 1; 21-day cycle with G-CSF on Day 8)
Number of subjects: 51
Study 36871042 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2811 (various doses from 15 to 600 mg)
Number of subjects: 51
Study 36871042 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2811 (various doses)
Number of subjects: 51
Study 36871101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Covid-19 vaccine (2 doses, 21 days apart)
Number of subjects: 35
Study 36871212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-management education and support (SMES) program using advertising principles
Number of subjects: 4761
Study 36871212 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4761
Study 36871213 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic letters emphasizing cardiovascular benefits of influenza vaccination
Number of subjects: 964870
Study 36871213 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 964870